Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

被引：1
|
作者：
Kim, H. [1 ]
Vu, P. [2 ]
Harrow, K. [3 ]
Liang, C. [4 ]
Selvaggi, G. [3 ]
Weihe, E. [2 ]
Mitchell, W. [2 ]
Bazhenova, L. [2 ]
Patel, S. [2 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA
[3] Xcovery Holdings Inc, Palm Beach Gardens, AL USA
[4] Xcovery Holdings Inc, Palm Beach Gardens, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; ALK; ensartinib;
D O I：
10.1016/j.jtho.2019.08.1208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-57
引用
收藏
页码：S577 / S578
页数：2
相关论文
共 50 条
  • [41] Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
    Straughan, David M.
    Azoury, Said C.
    Shukla, Vivek
    CURRENT DRUG TARGETS, 2016, 17 (06) : 739 - 745
  • [42] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [43] Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer
    Funazo, Tomoko
    Morita, Kyohei
    Ikegami, Naoya
    Konishi, Chisato
    Nakao, Satoshi
    Ariyasu, Ryo
    Taki, Masato
    Nakagawa, Kazuhiko
    Hwang, Moon Hee
    Yoshimura, Chie
    Wakayama, Toshiaki
    Nishizaka, Yasuo
    INTERNAL MEDICINE, 2017, 56 (17) : 2317 - 2320
  • [44] Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
    Solomon, B.
    Wilner, K. D.
    Shaw, A. T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (01) : 15 - 23
  • [45] Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
    Tan, Aaron C.
    Pavlakis, Nick
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [46] Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 203 - 214
  • [47] Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
    Park, Heae Surng
    Lee, June Koo
    Kim, Dong-Wan
    Kulig, Kimary
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    LUNG CANCER, 2012, 77 (02) : 288 - 292
  • [48] Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
    Berghmans, Thierry
    Remmelink, Myriam
    Awada, Ahmad
    LUNG CANCER-TARGETS AND THERAPY, 2012, 3 : 91 - 99
  • [49] IMMUNOHISTOCHEMICAL SCREENING FOR ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Lee, June Koo
    Park, Heae Surng
    Kim, Dong-Wan
    Kulig, Kimary
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Deo Seog
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S294 - S295
  • [50] Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
    Chayab, Lara
    Leighl, Natasha B.
    Tadrous, Mina
    Warren, Christine M.
    Wong, William W. L.
    CURRENT ONCOLOGY, 2025, 32 (01)
12345